MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Search

Vanda Pharmaceuticals Inc

Gesloten

4.13 -5.49

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.04

Max

4.38

Belangrijke statistieken

By Trading Economics

Inkomsten

412K

-4.9M

Verkoop

5.5M

53M

EPS

-0.084

Winstmarge

-9.236

Werknemers

368

EBITDA

727K

-8.3M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+277.57% upside

Dividenden

By Dow Jones

Volgende Winsten

7 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

63M

315M

Vorige openingsprijs

9.62

Vorige sluitingsprijs

4.13

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Vanda Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 apr 2025, 22:38 UTC

Populaire aandelen

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

4 apr 2025, 21:53 UTC

Marktinformatie

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

4 apr 2025, 21:44 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

4 apr 2025, 21:00 UTC

Top Nieuws

Americans Were Souring on Trump's Economic Plans Even Before Tariff Bloodbath -- WSJ

4 apr 2025, 20:52 UTC

Marktinformatie

Peloton Likely to Escape Tariffs Unscathed -- Market Talk

4 apr 2025, 20:52 UTC

Top Nieuws

Trump Can Cut Teacher-Training Programs For Now, Supreme Court Says -- WSJ

4 apr 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

4 apr 2025, 20:48 UTC

Top Nieuws

The Score: Nike, Apple, Stellantis and More Stocks That Defined the Week -- WSJ

4 apr 2025, 20:45 UTC

Top Nieuws

Hiring Defied Expectations in March, With 228,000 New Jobs -- 6th Update

4 apr 2025, 20:32 UTC

Top Nieuws

Dow Tumbles 2,000 Points, Bonds Rally After China Retaliates Against Trump Tariffs -- WSJ

4 apr 2025, 20:21 UTC

Top Nieuws

China Hits Back at Trump With Sweeping Tariffs on All U.S. Goods -- Update

4 apr 2025, 20:00 UTC

Top Nieuws

Republicans March Ahead on Trump's Tax Cuts as Tariffs Kick In -- WSJ

4 apr 2025, 19:51 UTC

Marktinformatie

Dollar Recovers While Recession Fears Grip Wall Street -- Market Talk

4 apr 2025, 19:37 UTC

Top Nieuws

Trump's Team is Getting the Bond Rally It Wanted. But for the Wrong Reasons. -- WSJ

4 apr 2025, 19:32 UTC

Marktinformatie

Oil Selloff Continues as China Responds to U.S. Tariffs -- Market Talk

4 apr 2025, 19:28 UTC

Top Nieuws

U.S. Stocks Fall Further After China Retaliates Against Trump Tariffs -- Update

4 apr 2025, 19:15 UTC

Marktinformatie

Costco Gold, Membership Fees Could Help Cushion from Tariff Costs -- Market Talk

4 apr 2025, 19:12 UTC

Top Nieuws

Powell Warns of Higher Prices, Weaker Growth After Tariff Plan -- 3rd Update

4 apr 2025, 19:11 UTC

Marktinformatie

U.S. Natural Gas Falls as Global Selloff Continues -- Market Talk

4 apr 2025, 19:09 UTC

Marktinformatie

Mexican Stocks, Peso Tumble as Global Rout Continues -- Market Talk

4 apr 2025, 19:09 UTC

Top Nieuws

Trump Grants 75-Day Extension to Reach TikTok Deal -- Second Update

4 apr 2025, 19:00 UTC

Marktinformatie

Fed Has Limited Options to Counter Tariffs -- Market Talk

4 apr 2025, 18:53 UTC

Marktinformatie

Brace for Trump's Tariff Order to Remain in Place for Extended Period -- Market Talk

4 apr 2025, 18:51 UTC

Marktinformatie

Morgan Stanley Analysts Outline Paths to Recession -- Market Talk

4 apr 2025, 18:44 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

4 apr 2025, 18:44 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

4 apr 2025, 18:44 UTC

Marktinformatie

Tariffs Won't Achieve What Trump Wants, Morgan Stanley Says -- Market Talk

4 apr 2025, 18:43 UTC

Acquisities, Fusies, Overnames

Trump Extends Deadline for TikTok Ban Another 75 Days. ByteDance Says 'An Agreement Has Not Been Executed.' -- Barrons.com

4 apr 2025, 18:43 UTC

Acquisities, Fusies, Overnames

Trump Extends TikTok Ban Deadline A Second Time As Deal Chatter Swirls -- IBD

4 apr 2025, 18:39 UTC

Marktinformatie

Protectionism is Back, And Recession Could Follow, Morgan Stanley Says -- Market Talk

Peer Vergelijking

Prijswijziging

Vanda Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

277.57% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 16.5 USD  277.57%

Hoogste 20 USD

Laagste 13 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Vanda Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Technische score

By Trading Central

N/A / 4.74Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Very Strong Bearish Evidence

Lange Termijn

Strong Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.